Q-omics provides the consensus-scored SPACA4 profile across patient tissues and cancer cell-line models. SPACA4 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SPACA4 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, SPACA4 RNA expression shows 12,567 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight HNSC, and BRCA as cancer lineages where SPACA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPACA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPACA4 survival associations across molecular data types. SPACA4 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPACA4 RNA expression–survival associations across cancer types. High SPACA4 expression shows unfavorable associations in KIRC, ACC and ESCA, but favorable associations in HNSC, MESO and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SPACA4 RNA expression.
This table summarizes SPACA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPACA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPACA4 shows lower tumor expression in HNSC, KIRC and KICH and higher tumor expression in BRCA, PAAD and STAD. The HNSC box plot shows higher SPACA4 RNA expression in normal versus tumor tissue (log2 FC = −0.863, t-test p < 0.001).
This table shows molecular features associated with SPACA4 in patient tissues and cancer cell lines. In patient samples, SPACA4 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SPACA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
